Clinical trials: CNS Malignancy
Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed.
- Conditions
- Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT02867592
- Testing
- Cabozantinib, Cabozantinib S-malate, Pharmacological Study
- Where
- 142 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Cancer Institute (NCI)
Hypothyroidism, Brain Tumor
Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors
Primary Objectives: 1. Assess whether combined treatment with Levothyroxine and Liothyronine improves learning and memory. 2. Explore the relationship between T3 treatment and other domains of cognitive function, quality of life…
- Trial name
- NCT00488644
- Testing
- Levothyroxine, Liothyronine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Glioblastoma Multiforme
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
PURPOSE AND OBJECTIVES: Primary Objective To evaluate the activity of Sorafenib plus protracted, daily temozolomide in patients with recurrent glioblastoma multiforme (GBM) as measured by 6-month PFS.
- Trial name
- NCT00597493
- Testing
- Sorafenib and Temozolomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Duke University
Glioblastoma Multiforme
Amgen 386 for Recurrent Glioblastoma
Primary Objectives Cohort A -- monotherapy: To determine the efficacy of AMG 386 in participants with recurrent glioblastoma (GBM) as measured by 6-month progression-free survival (PFS6) Cohort B - combination therapy: Phase I To…
- Trial name
- NCT01290263
- Testing
- Amgen 386, Bevacizumab
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Dana-Farber Cancer Institute
Malignant Central Nervous System Neoplasm, Metastatic Malignant Neoplasm in the Central Nervous System
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors
This early phase I trial studies how well hyperpolarized carbon C 13 pyruvate magnetic resonance imaging works in detecting lactate and bicarbonate in participants with central nervous system tumors.
- Trial name
- NCT03565367
- Testing
- Gadolinium, Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Daniel M. Spielman
Adult Giant Cell Glioblastoma, Adult Glioblastoma
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
This randomized phase II trial is studying how well GDC-0449 works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00980343
- Testing
- vismodegib, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- 9 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
Background: Enzalutamide is given to treat metastatic prostate cancer. But it takes 4 pills to deliver the effective dose. This can be difficult for people already taking multiple drugs.
- Trial name
- NCT03478904
- Testing
- Enzalutamide Liquid, Enzalutamide Capsule
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Sturge-Weber Syndrome
Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome
The purpose of this study is to determine the tolerability and optimal dose of cannabidiol (CBD) as an simultaneous treatment in children and young adults with Sturge-Weber syndrome (SWS) and drug resistant epilepsy.
- Trial name
- NCT02332655
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Anne Comi, MD
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
This phase I/II trial is studying the side effects and the best dose of RO4929097 to see how well it works when given together with bevacizumab compared to bevacizumab alone in treating patients with progressive or recurrent…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT01189240
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, bevacizumab, laboratory biomarker analysis
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Cerebral Cavernous Malformation
Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial
This phase I/II randomized, placebo-controlled, double-blinded, single-site clinical trial is designed to investigate the effect of a prolonged course of atorvastatin versus placebo on CCM lesional iron deposition assessed by…
- Trial name
- AT CASH EPOC (NCT02603328)
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Chicago
Brain Cancer
Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT)
The goal of this clinical research study is to compare IMRT with IMPT in patients with glioblastoma. Researchers want to learn about cognitive side effects (mental status changes) that may occur, such as memory loss and impaired…
- Trial name
- NCT01854554
- Testing
- IMPT, IMRT, Cognitive Tests
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- M.D. Anderson Cancer Center
Mood, Cancer Brain
Managing Cancer and Living Meaningfully
The purpose of this study is to pilot test an empirically supported psychotherapeutic intervention, Managing Cancer and Living Meaningfully (CALM).
- Trial name
- CALM (NCT04646213)
- Testing
- Managing Cancer and Living Meaningfully (CALM) Therapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Virginia Commonwealth University
Cushing's Syndrome
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.
- Trial name
- SEISMIC (NCT00569582)
- Testing
- mifepristone
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Corcept Therapeutics
Cord Compression
Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression
The purpose of this research study is to look at a combination treatment of radiation therapy and a drug called Abraxane to treat epidural spinal cord compression.
- Trial name
- NCT03655080
- Testing
- Radiation therapy, nab-Paclitaxel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Washington University School of Medicine
Relapsed Solid Tumor, Refractory Solid Tumor
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did…
- Trial name
- NCT04238819
- Testing
- Abemaciclib, Irinotecan, Temozolomide
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
HER-2 Positive Breast Cancer, Metastatic Malignant Neoplasm to Brain
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Evaluate the safety and tolerability and determine the maximum tolerated dose (MTD) of the combination of tesevatinib and trastuzumab in subjects with HER2-positive metastatic breast cancer
- Trial name
- NCT02154529
- Testing
- Tesevatinib, Trastuzumab
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Kadmon Corporation, LLC
Glioblastoma, Adult-type Diffuse Gliomas
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent gliomas, circumscribed astrocytic gliomas, and glioneuronal and neuronal tumors with an activating…
- Trial name
- FIGHT-209 (NCT05267106)
- Testing
- Pemigatinib
- Where
- 79 sites in United States, Denmark and 7 more
- Volunteers
- 83 people
- Sponsor
- Incyte Corporation
Pituitary Adenoma
Surgical Debulking of Pituitary Adenomas
This is a randomized, multicenter trial with stratification done by a single radiologist at the coordinating center (NYU), and patients with comparable disease will be randomized to Sandostatin LAR treatment administered 1 time…
- Trial name
- NCT01371643
- Testing
- Octreotide LAR, transsphenoidal surgery
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- NYU Langone Health
Atypical Meningioma, Anaplastic Meningioma
A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
- Conditions
- Atypical Meningioma, Anaplastic Meningioma, Hemangiopericytoma
- Trial name
- NCT03016091
- Testing
- Pembrolizumab
- Where
- 2 sites in Israel
- Volunteers
- 18 people
- Sponsor
- Rabin Medical Center
Glioblastoma Multiforme, Glioma
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
Current treatments for Glioblastoma Multiforme (GBM), the most common and malignant primary brain tumor are inadequate and as such, the median survival for most patients with GBM is on the order of months, even after…
- Conditions
- Glioblastoma Multiforme, Glioma, Astrocytoma, Brain Tumor
- Trial name
- NCT01044966
- Testing
- ITV DepoCyt + Temozolomide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medical University of South Carolina